Cipla is charting its next growth phase with a strong focus on innovation, complex generics, and biosimilars. The company plans significant...

As Cipla approaches its centenary, the company is redefining its strategy by prioritizing innovation to amplify revenues. With ambitions to...

Nilesh Shah, MD and CEO of Envision Capital, is buying through market volatility but steering clear of IT, questioning the validity of curr...

Sun Pharma anticipates strong growth in the coming years. The company expects a high single-digit increase in its overall sales by FY2027. ...

Dr Reddys Laboratories has launched its oral semaglutide biosimilar for type 2 diabetes in India. The drug, Obeda, is available in three ta...

Indian pharmaceutical firms are exporting millions of dollars worth of powerful tapentadol opioids to West Africa, fueling a deadly drugs e...

India’s cancer treatment landscape is seeing a shift as lower-cost immunotherapy drugs developed in China and marketed through Indian partn...

Over a dozen Indian companies have launched generic versions of the GLP1 drug used for diabetes and weight management since the expiry of N...

Indian markets saw volatile trading on Thursday, closing nearly unchanged despite positive signals. Several companies including SBI, Titan,...

Sun Pharma, led by Dilip Shanghvi, has agreed to acquire US-based Organon in an all-cash deal worth $11.75 billion, marking the largest acq...

US company’s board meeting is happening this weekend to finalise decision; an announcement is imminent later tonight or by Monday. Mumbai H...

Indian markets faced pressure extending a corrective phase. Key companies like RIL, IDFC First Bank, and Paytm reported their financial res...

Alkem Labs, a leading Indian drug maker, is set for a top management change. Vikas Gupta, the CEO for nearly three years, is expected to de...

A new weight-loss drug, retatrutide, is generating excitement. This investigational medicine targets three hormone receptors, offering a po...

Experts predict the launch pipelines for generic players in the US will be impacted as drugs coming off patent may see a fall in the 2017-2...

Several mid-sized Indian drug makers heavily dependent on the United States are beginning to suffer because consolidation in the US pharmac...

Europe is wooing Indian drug makers to develop new medicines for HIV/AIDS, tuberculosis and malaria with home-grown companies.